A Phase II, Multi-Center, Open-Label, Trial of PR104 in Treatment Naive and Sensitive-relapse Small Cell Lung Cancer.

Trial Profile

A Phase II, Multi-Center, Open-Label, Trial of PR104 in Treatment Naive and Sensitive-relapse Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs PR 104 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Sep 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 26 Jun 2008 Additional trial identifier 2008-001 reported by Barbara Ann Karmanos Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top